A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years

Over the past decade, pharmaceutical maker Pfizer (NYSE: PFE) has severely lagged the market. Dividends reinvested aside, the stock is in the red over this period, while the S&P 500 is up by almost 230%.Now for the good news: Although Pfizer has encountered some issues, the company is quietly setting up a solid foundation. And investors who get in on the act now might be handsomely rewarded down the road.Pfizer has dealt with several headwinds in the past few years. Here are three of the biggest. First, the company failed to keep up the torrid pace of revenue and earnings growth it had during the early pandemic years. Having developed one of the leading coronavirus vaccines on the market, the drugmaker benefited immensely. But that tailwind has since evaporated.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool